News Daily News Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure Michael O'Riordan December 30, 2025
News Conference News ESC 2025 Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support Todd Neale August 30, 2025
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Daily News AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD Caitlin E. Cox December 28, 2021
News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Features ‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19 Michael O'Riordan April 07, 2020
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Conference News ESC 2016 ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH Michael O'Riordan August 28, 2016
News Daily News Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs Michael O'Riordan March 25, 2016
News Daily News Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina Michael O'Riordan March 25, 2016
News Daily News Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond December 23, 2015